Patents Assigned to Bayer Schering Pharma Aktiengesellschaft
  • AQUEOUS FORMULATIONS OF (2-HYDROXYMETHYL-INDANYL-4-OXY)-PHENYL-4,4,4-TRIFLUOROBUTANE-1-SULFONATE
    Publication number: 20110065788
    Abstract: The invention relates to aqueous formulations containing (?)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.
    Type: Application
    Filed: November 18, 2010
    Publication date: March 17, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Bernd Kühn, Antje Brück, Yoshifumi Katakawa, Masami Yasui
  • Crystalline potassium salt of lipoxin A4 analogs
    Patent number: 7906678
    Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: March 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Tilo Haag, Danja Grossbach, Gabriele Winter, Michael Sander, Wolfgang Beckmann, Klaus Bartel, Christian Dinter
  • PROCESS FOR THE PURIFICATION OF INTERLEUKIN-4 AND ITS MUTEINS
    Publication number: 20110060128
    Abstract: This invention relates generally to a method for purifying Interleukin-4 or related variants from an Escherichia coli culture medium, where Interleukin-4 and its derivatives are expressed as insoluble protein aggregates, so-called inclusion bodies.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Jörg Peters, Torsten Minuth, Hans-Georg Dellweg
  • PYRIMIDOTHIENOINDAZOLES
    Publication number: 20110053928
    Abstract: The invention relates to novel pyrimidothienoindazoles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 3, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Chengzhi Zhang, Roger Smith, Gan Wang, Sharad Verma, Qingming Zhu
  • IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE
    Publication number: 20110053929
    Abstract: The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.
    Type: Application
    Filed: June 28, 2008
    Publication date: March 3, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Stephan Siegel, Andreas Wilman, Susanne Röhrig, Niels Svenstrup, Mark Jean Gnoth, Stefan Heitmeier, Ulrich Rester, Adrian Tersteegen, Michael Gerisch
  • Isolated human antibodies that bind epitopes on RG1
    Patent number: 7893217
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
    Patent number: 7893210
    Abstract: A method for renaturation of proteins comprising adding to a solution of denatured, chemically modified or reduced proteins a refolding buffer containing a primary, secondary or tertiary amine. Said method has been applied, for example, to interleukin-4 and bovine pancreatic trypsin inhibitor (BPTI), which were previously (i) solubilized in the presence of guanidinium hydrochloride as chaotronic agent, and (ii) subjected to sulfitolysis.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jörg Peters, Torsten Minuth
  • Heterocyclic derivatives
    Patent number: 7893073
    Abstract: The invention relates to novel 3,4-dihydropyrimidin-2(1H)-one derivatives having the formula processes for their preparation, and their use in compositions, and in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Heike Gielen-Haertwig, Barbara Albrecht, Jörg Keldenich, Volkhart Li, Josef Pernerstorfer, Karl-Heinz Schlemmer, Leila Telan
  • NOVEL AZA-BICYCLIC COMPOUNDS AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE
    Publication number: 20110038857
    Abstract: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.
    Type: Application
    Filed: November 14, 2007
    Publication date: February 17, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Hartmut Schirok, Joachim Mittendorf, Johannes-Peter Stasch, Frank Wunder
  • Methods for treating disease-states associated with RG1 using immunoconjugates
    Patent number: 7887804
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE
    Publication number: 20110034433
    Abstract: The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.
    Type: Application
    Filed: December 9, 2008
    Publication date: February 10, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Franz Von Nussbaum, Dagmar Karthaus, Sonja Anlauf, Martina Delbeck, Volkhart Min-Jian Li, Daniel Meibom, Klemens Lustig, Jens Schamberger
  • CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE
    Publication number: 20110021487
    Abstract: The present application relates to novel cycloalkoxy-substituted 4-phenyl-3,5-dicyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.
    Type: Application
    Filed: January 31, 2009
    Publication date: January 27, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Walter Hübsch, Peter Nell, Frank Süssmeier, Alexandros Vakalopoulos, Daniel Meibom, Barbara Albrecht-Küpper, Katja Zimmermann
  • NEW MODULATING MOLECULES FOR AN IMPROVED REGULATED EXPRESSION SYSTEM
    Publication number: 20110020925
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: April 11, 2008
    Publication date: January 27, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Maxine Bauzon, Peter Droescher, Richard N. Harkins, Terry Hermiston, Peter Kretschmer, Konstantin Levitsky, Paul Szymanski
  • SUBSTITUTED PIPERIDINES
    Publication number: 20110021489
    Abstract: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.
    Type: Application
    Filed: May 27, 2010
    Publication date: January 27, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Dirk HEIMBACH, Susanne Röhrig, Yolanda Cancho Grande, Eckhard Bender, Katja Zimmermann, Anja Buchmüller, Christoph Gerdes, Mark Jean Gnoth, Kersten Matthias Gericke, Mario Jeske
  • SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110021493
    Abstract: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.
    Type: Application
    Filed: September 2, 2008
    Publication date: January 27, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Schirok, Ying Li-Sommer, Michael Brands, Mario Lobell, Adrian Tersteegen, Herbert Himmel, Karl-Heinz Schlemmer, Dieter Lang, Kirsten Petersen, Matthias Renz, Dominik Mumberg, Jens Hoffman, Gerhard Siemeister, Ulf Bömer
  • SUBSTITUTED HETEROCYCLES AND USE THEREOF
    Publication number: 20110015241
    Abstract: The invention relates to substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.
    Type: Application
    Filed: May 25, 2007
    Publication date: January 20, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Michael Härter, Tobias Wunberg, Susanne Röhrig, Stefan Heitmeier
  • 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative
    Publication number: 20110015162
    Abstract: The invention relates to 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid ?-lactone derivatives with the general chemical formula I, and R4, R6a, R6b, R7 and Z have the meanings stated in claim 1, and their solvates, hydrates, stereoisomers and salts. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action.
    Type: Application
    Filed: December 23, 2008
    Publication date: January 20, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Klar, Joachim Kuhnke, Rolf Bohlmann, Jan Huebner, Sven Ring, Thomas Frenzel, Frederik Menges, Steffen Borden, Hans Peter Muhn, Katja Prelle
  • TAMPER-PROOF CLOSURE HAVING A RETAINING PIN
    Publication number: 20110015578
    Abstract: The invention relates to a tamperproof seal for a container or a syringe, with a lockable conical adapter which is sealed in a sterile manner by means of a rubber stopper and is protected by a safety sleeve, wherein the safety sleeve, which is pushed non-releasably onto the conical adapter lock, comprises a retaining part, a break-off part and a break-off zone located between said parts. The break-off part encloses the rubber stopper without radical contact. It has a retaining pin, the free end of which rests axially on the rubber stopper—when the tamperproof seal is fitted, and it has at least two open apertures. The length of the break-off part corresponds to at least twice the length of the internal thread of the conical adapter lock. The present invention produces a tamperproof seal which ensures safe handling of the combination comprising the container or syringe and tamperproof seal.
    Type: Application
    Filed: February 24, 2009
    Publication date: January 20, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventor: Christiane Lowke
  • 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS
    Publication number: 20110009367
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: March 4, 2010
    Publication date: January 13, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Maria Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS
    Publication number: 20110003778
    Abstract: The present invention provides the use of mineralocorticoid receptor antagonists for preparing a medicament for the treatment of endometriosis. The present invention relates in particular to an improved therapeutic composition for endometriosis which has a more favorable activity and side-effect profile than treatment therapies currently available. Using a mineralocorticoid receptor antagonist, it is possible to threat endometriosis permanently without any loss of bone mass.
    Type: Application
    Filed: February 28, 2008
    Publication date: January 6, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Carsten Moeller, Ulrike Kaufmann-Reiche, Anja Schmidt, Ulrike Fuhrmann, Oliver-Martin Fischer